License and Collaboration Agreements - Additional Information (Details) - USD ($)				1 Months Ended				3 Months Ended				9 Months Ended		10 Months Ended	12 Months Ended			29 Months Ended	50 Months Ended
	Dec. 31, 2022	Jul. 13, 2020	Apr. 30, 2019	Feb. 28, 2021	Jan. 31, 2021	Sep. 30, 2017	Aug. 31, 2017	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
License And Collaboration Agreements [Line Items]
Issuance of common stock											$ 326,246,000
Gross proceeds												$ 220,235,000	$ 433,776,000
Cost sharing receivable, current								$ 871,000				871,000		$ 871,000				$ 871,000	$ 871,000	$ 1,049,000
Development expense								71,254,000		$ 51,801,000		206,412,000	110,636,000
Compensation expense recognized								14,585,000		6,002,000		40,713,000	13,934,000
Research and Development
License And Collaboration Agreements [Line Items]
Compensation expense recognized								7,949,000		3,075,000		$ 21,087,000	7,179,000
WuXi Biologics License Agreement
License And Collaboration Agreements [Line Items]
Clinical and regulatory milestones achieved														16,500,000
Range of tiered royalty payments on net sales												high single-digits to low teens
Development milestone expense								0				$ 10,000,000.0
WuXi Biologics License Agreement | Research and Development
License And Collaboration Agreements [Line Items]
Upfront cash payment														500,000
Sub-license fees incurred																			11,300,000
Upfront and milestone payments																			41,000,000.0
WuXi Biologics License Agreement | Maximum
License And Collaboration Agreements [Line Items]
Clinical, regulatory and commercialization milestone payments							$ 375,000,000.0
Abmuno License Agreement
License And Collaboration Agreements [Line Items]
Upfront and milestone payments												14,600,000
Development milestone expense								0		3,000,000.0		5,000,000.0	3,000,000.0
Clinical, regulatory and commercialization remaining milestone payments												93,000,000.0
Gilead Collaboration Agreement | Gilead
License And Collaboration Agreements [Line Items]
Upfront cash payment		$ 175,000,000.0										175,000,000
Collaboration term for current and future clinical programs		10 years
Contingent milestone payments receivable		$ 400,000,000
Additional collaboration term for programs entering clinical development prior to end of collaboration term		3 years
Option fee per program for all other programs entering clinical development to exercise option		$ 150,000,000
Present value of research and development information access rights payment related to year 2022		100,000,000.0
Premium on stock purchased		90,600,000
Initial transaction price		365,600,000
Option payment upon achievement of certain development milestones		250,000,000.0
Deferred revenue related to etrumadenant option								127,000,000.0				$ 127,000,000.0		127,000,000.0				127,000,000.0	127,000,000.0
Etrumadenant option initial term of agreement												4 years
Option payment upon achievement of certain development milestones		$ 275,000,000.0
Deferred revenue related to domvanalimab option								36,700,000				$ 36,700,000		36,700,000				36,700,000	36,700,000
Domvanalimab option recognized term												1 year
Current and future programs exclusive access period		10 years
Additional payment due at each of the fourth, sixth, and eighth anniversaries of the agreement		$ 100,000,000
Contingent milestone payment start period		2022
Contractual obligation for first payment		$ 100,000,000
Performance obligation period		4 years
Contractual obligation remaining amount not obligated to pay		$ 300,000,000
Deferred revenue related to research and development pipeline								98,600,000				$ 98,600,000		98,600,000				98,600,000	98,600,000
Future development and promotion costs contract liability								9,700,000				9,700,000		9,700,000				9,700,000	9,700,000
Revenue recognized from this performance obligation												0
Consultant and legal fees		7,300,000
Amortization expense								100,000				300,000
Cost sharing receivable								3,900,000				3,900,000		3,900,000				3,900,000	3,900,000
Clinical and regulatory milestones achieved												0
Gilead Collaboration Agreement | Gilead | Scenario Forecast
License And Collaboration Agreements [Line Items]
Consulting fees to third party exercises option	$ 4,500,000
Gilead Collaboration Agreement | Gilead | Prepaid Expenses and Other Current Assets
License And Collaboration Agreements [Line Items]
Cost sharing receivable, current								1,000,000.0				1,000,000.0		1,000,000.0				1,000,000.0	1,000,000.0
Gilead Collaboration Agreement | Gilead | Other Noncurrent Assets
License And Collaboration Agreements [Line Items]
Cost sharing receivable, noncurrent								2,900,000				2,900,000		$ 2,900,000				2,900,000	$ 2,900,000
Gilead Collaboration Agreement | Gilead | Minimum
License And Collaboration Agreements [Line Items]
Option fee per program for current clinical programs to exercise option		200,000,000
Gilead Collaboration Agreement | Gilead | Minimum | Scenario Forecast
License And Collaboration Agreements [Line Items]
Consulting fees to third party exercises option	2,000,000.0
Gilead Collaboration Agreement | Gilead | Maximum
License And Collaboration Agreements [Line Items]
Contingent milestone payments receivable		400,000,000
Option fee per program for current clinical programs to exercise option		275,000,000
Clinical and regulatory milestones achieved		500,000,000
Gilead Collaboration Agreement | Gilead | Maximum | Scenario Forecast
License And Collaboration Agreements [Line Items]
Consulting fees to third party exercises option	$ 4,500,000
Purchase Agreement
License And Collaboration Agreements [Line Items]
Direct offering cost		1,900,000
Purchase Agreement | Gilead
License And Collaboration Agreements [Line Items]
Issuance of common stock		$ 200,000,000		$ 220,400,000					$ 220,296,000	107,468,000
Issuance of common stock, shares		5,963,029		5,650,000	5,650,000
Shares issued, price per share		$ 33.54		$ 39.00	$ 39.00
Percentage of option to purchase maximum shares of common stock		35.00%
Period over common stock to be purchased		5 years
Percentage of premium purchase price of common stock		20.00%
Trailing days average closing price		5 days
Share Price		$ 33.54
Gross proceeds		$ 107,500,000			$ 220,400,000
Premium on stock purchased												$ 90,600,000
Taiho Agreement | Taiho Pharmaceutical Co., Ltd
License And Collaboration Agreements [Line Items]
Option period						5 years
Option ending period						2022-09
Non refundable and non creditable cash payments																	$ 35,000,000.0
Payment received for license agreement															$ 5,000,000.0	$ 5,000,000.0	$ 25,000,000.0
Range of royalties receivable on net sales												high single-digits to mid-teens
Royalties payable description												Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term).
Non-refundable, non-creditable upfront cash payments												$ 35,000,000.0
Estimated performance period												5 years
Clinical and regulatory milestones achieved												$ 0
Sales milestone or royalty revenue recognized												0
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Minimum
License And Collaboration Agreements [Line Items]
Payment for option exercise						$ 3,000,000.0
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Maximum
License And Collaboration Agreements [Line Items]
Contingent milestone payments receivable						145,000,000.0
Payment for option exercise						15,000,000.0
Additional clinical and regulatory milestone payments receivable						$ 130,000,000.0
Strata Agreement | Strata Oncology Inc
License And Collaboration Agreements [Line Items]
Development cost recorded within research and development expenses								700,000		300,000		1,800,000	1,200,000					4,500,000
Development cost reimbursed								100,000		$ 100,000		300,000	$ 200,000					900,000
Number of restricted shares of common stock issued			1,257,651
Fair value of restricted shares of common stock issued			$ 15,000,000.0
Strata Agreement | Strata Oncology Inc | Research and Development
License And Collaboration Agreements [Line Items]
Milestone payments																		$ 2,500,000
AstraZeneca Agreement
License And Collaboration Agreements [Line Items]
Development cost recorded within research and development expenses								300,000				600,000
WuXi CD-39 Agreement | WuXi Biologics License Agreement
License And Collaboration Agreements [Line Items]
Development milestone expense								$ 0				$ 0